Company Overview of Enumeral Biomedical Holdings, Inc.
Enumeral Biomedical Holdings, Inc. engages in discovering and developing antibody immunotherapies that help the immune system fight cancer and other diseases. It is developing antibodies against a number of classes of immunomodulatory proteins expressed on the surface of cells of the immune system for the treatment of cancer, autoimmune, and inflammatory diseases. Enumeral Biomedical Holdings, Inc. has a collaboration agreement with Merck Sharp & Dohme Corp.; and research contract with the National Cancer Institute. Enumeral Biomedical Holdings, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.
200 CambridgePark Drive
Cambridge, MA 02140
Founded in 2009
Key Executives for Enumeral Biomedical Holdings, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $174.6K
Co-Founder and Executive Chairman
Total Annual Compensation: $167.4K
Chief Accounting Officer, Vice President of Finance and Treasurer
Total Annual Compensation: $85.4K
Vice President of Business Development
Total Annual Compensation: $171.3K
Compensation as of Fiscal Year 2014.
Enumeral Biomedical Holdings, Inc. Key Developments
Enumeral Biomedical Holdings, Inc. Approves Amendment to the Certificate of Incorporation
Jun 19 15
Enumeral Biomedical Holdings, Inc. approved amendment to the certificate of incorporation at its AGM held on June 18, 2015.
Enumeral Biomedical Holdings, Inc. Announces Executive Appointments
Jun 4 15
Enumeral Biomedical Holdings, Inc. announced the expansion of its Scientific Advisory Board with the appointments of Giulio Draetta, M.D., Ph.D., and Kai Wucherpfennig, M.D., Ph.D., recognized leaders in the fields of tumor biology and cancer immunotherapy. Dr. Draetta is Director of the Institute for Applied Cancer Science at M.D. Anderson Cancer Center, where he is also Professor of Genomic Medicine and Professor of Molecular and Cellular Oncology. His research focuses on identifying disease-driving genes associated with melanoma, glioblastoma and pancreatic cancer. Prior to joining M.D. Anderson, Dr. Draetta was the Chief Research Business Development Officer and Deputy Director of the Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute. He previously served as Merck Research Laboratories’ Vice President and Worldwide Basic Franchise Head of Oncology. Dr. Draetta is a co-founder of Karyopharm, which develops inhibitors of nuclear transport targets for the treatment of cancer and other diseases. He also was the co-founder and Head of Research of Mitotix (acquired by GPC Biotech), where he established programs in cancer, inflammation and infectious diseases. Dr. Wucherpfennig, M.D., Ph.D., is Professor and Co-chair of the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute and Professor of Neurology at Harvard Medical School. His work focuses on the discovery of genes that control the activity of cytotoxic T cells in the tumor microenvironment with in vivo models and using these insights for the development of cancer immunotherapies. Dr. Wucherpfennig election as a Fellow in the American Society for the Advancement of Science, his election as a member of the Henry Kunkel Society at Rockefeller University, and his election as a member of the American Society for Clinical Investigation.
Enumeral Biomedical Holdings, Inc. to Amend Certificate of Incorporation
May 20 15
Enumeral Biomedical Holdings, Inc. announced at the AGM to be held on June 18, 2015, it will propose to grant the board of directors discretionary authority to amend the company's certificate of incorporation to effectuate a reverse stock split of the company's Common Stock, $0.001 par value, by a ratio of no less than one-for-five and no more than one-for-fifteen with such ratio to be determined by the
board in its sole discretion and with such Reverse Split to be effective at such time and date, if at all, as determined by the board in its sole discretion, it being understood that the purpose of such Reverse Split is to attempt to obtain a listing on either The Nasdaq Capital Market or the NYSE MKT.
Similar Private Companies By Industry
Recent Private Companies Transactions